Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with

Read more

Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

​Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfize...

Read more

Ysios Capital wins CataloniaBio & HealthTech Biosuccess Award

by CataloniaBio

CataloniaBioHT also recognised the career of Antonio Parente. The awards were given out yesterday by Catalan Minister of Health Alba Vergés at the CataloniaBioHT Gala Dinner at the Sant Pau Art Nouve...

Read more

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...

Read more

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

The financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...

Read more

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...

Read more

CorWave Raises $17.1 Million in Series B Financing

by Ysios Capital

CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...

Read more

Parkinson’s disease: Prexton Therapeutics, participated by Ysios Capital, completes phase 1 clinical trial

by Ysios Capital

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

Read more

CVRx® Secures $113 Million in New Financing

by Ysios Capital

CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

as personas con trastorno límite de la ...

by Universidad Autónoma de Madrid

Un equipo español ha presentado datos relevantes para avanzar en la c...

Photos Stream